Goldman Sachs analyst Salveen Richter downgraded Sarepta (SRPT) to Neutral from Buy with a $29 price target
Claim 55% Off TipRanks
Trade SRPT with leveragePublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta death shows favorable SGT-003 profile, says H.C. Wainwright
- Sarepta price target lowered to $75 from $100 at Wells Fargo
- Sarepta price target lowered to $29 from $89 at Barclays
- Sarepta initiated with a Peer Perform at Wolfe Research
- Buy Rating for Sarepta Therapeutics Amid Safety Concerns and Regulatory Challenges